Skip to content

US · IBIO · BIOTECHNOLOGY

iBio, Inc. (IBIO) intrinsic value and stock valuation

$0.80as of 2026-11-21 · Mkt cap 22.26M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

iBio, Inc. DCF and intrinsic value

InvestorsCraft values IBIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IBIO’s statements →

iBio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 ibioinc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$400K-24.6% 5y CAGRd
20112025
Net income
-$-18.38M
20112025
Free cash flow
-$-15.32M
20112025
Total equity
$14.9M-23.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$400K$230K$0.00$1.88M$2.37M
Operating income-$-18.6M-$-16.63M-$-29.34M-$-29.7M-$-31.11M
Net income-$-18.38M-$-24.91M-$-65.01M-$-50.39M-$-23.21M
EPSd-$-1.75M-$-6.5M-$-106.57M-$-2.52B-$-59.51M
Operating cash flow-$-15.3M-$-18.55M-$-30.44M-$-37.8M-$-30.06M
Capital expenditure-$-20K-$-210K-$-5.74M-$-7.33M-$-5.16M
Free cash flow-$-15.32M-$-18.76M-$-36.17M-$-45.13M-$-35.23M
Total assets$23.2M$28.7M$41.2M$99.4M$147M
Total debt$3.51M$4.46M$17.1M$25.8M$32.7M
Net debt-$-5.07M-$-9.75M$9.75M$3.09M-$-44.68M
Total equity$14.9M$21.3M$15.4M$63.5M$108.6M
Cash and short-term investments$8.58M$14.2M$7.33M$33.5M$97M
Income statement
20252024202320222021
Revenue$400K$230K$0.00$1.88M$2.37M
Cost of revenue$0.00$0.00$0.00$3.79M$1.46M
Gross profit$400K$230K$0.00-$-1.91M$910K
Research and development expenses$8.31M$5.18M$10.3M$9.83M$9.99M
Selling, general and administrative expenses$10.7M$11.7M$18.5M$18M$21.9M
Other expenses$0.00$0.00$560K$0.00$140K
Operating expenses$19M$16.9M$29.3M$27.8M$32M
Cost and expenses$19M$16.9M$29.3M$31.6M$33.5M
Interest income$440K$360K$210K$180K$140K
Interest expense$210K$170K$80K$1.41M$2.45M
Depreciation and amortization$1.13M$1.25M$1.38M$3.79M$2.41M
Ebitda-$-17.04M-$-14.02M-$-27.85M-$-25.72M-$-28.55M
Operating income-$-18.6M-$-16.63M-$-29.34M-$-29.7M-$-31.11M
Total other income/expenses, net$230K$1.19M$30K$180K$7.9M
Income before tax-$-18.38M-$-15.44M-$-29.31M-$-29.51M-$-23.21M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-18.38M-$-24.91M-$-65.01M-$-50.39M-$-23.21M
Weighted average shares outstanding$10.5M$3.83M$610K$20K$390K
Weighted average diluted shares outstanding$10.5M$3.83M$610K$20K$390K
Balance sheet
20252024202320222021
Cash and short-term investments$8.58M$14.2M$7.33M$33.5M$97M
Net receivables$100K$710K$200K$6.1M$5.53M
Inventory$0.00$0.00$0.00$3.9M$30K
Total current assets$9.72M$15.7M$26.3M$45.1M$104.6M
Property, plant and equipment, net$5.28M$6.37M$7.55M$41.8M$34.7M
Goodwill and intangible assets$6.85M$5.37M$5.39M$4.85M$950K
Long-term investments$1.31M$1.3M$1.96M$7.63M$0.00
Total non-current assets$13.5M$13.1M$15M$54.3M$42.4M
Total assets$23.2M$28.7M$41.2M$99.4M$147M
Accounts payable$2.19M$360K$1.85M$4.26M$2.25M
Short-term debt$1.31M$950K$13.6M$22.3M$970K
Deferred revenue$1.2M$200K$0.00$100K$420K
Total current liabilities$6.11M$3.84M$21.6M$30.4M$6.64M
Long-term debt$2.2M$3.51M$3.48M$3.51M$31.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.2M$3.57M$4.24M$5.49M$31.8M
Capital lease obligations$2.74M$3.48M$3.48M$3.6M$32.1M
Total liabilities$8.3M$7.41M$25.8M$35.9M$38.4M
Common stock$20K$10K$20K$10K$10K
Retained earnings-$-332.22M-$-313.85M-$-288.94M-$-223.93M-$-173.63M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$-210K-$-60K
Total equity$14.9M$21.3M$15.4M$63.5M$108.6M
Total investments$1.31M$1.3M$1.96M$18.5M$19.6M
Total debt$3.51M$4.46M$17.1M$25.8M$32.7M
Net debt-$-5.07M-$-9.75M$9.75M$3.09M-$-44.68M
Cash flow statement
20252024202320222021
Net income-$-18.38M-$-24.91M-$-65.01M-$-29.51M-$-23.21M
Depreciation and amortization$290K$1.25M$1.38M$3.79M$2.41M
Stock-based compensation$1.53M$2.04M$4.39M$4.38M$1.59M
Change in working capital$480K-$-3.17M$5.87M$3.24M-$-11.15M
Accounts receivable$0.00$0.00$6.1M$4.21M-$-10.74M
Inventory$0.00$0.00-$-1.01M-$-3.87M$770K
Accounts payable$1.83M-$-1.49M-$-620K$1.24M$50K
Net cash provided by operating activities-$-15.3M-$-18.55M-$-30.44M-$-37.8M-$-30.06M
Investments in property, plant and equipment-$-20K-$-210K-$-5.74M-$-11.63M-$-4.92M
Acquisitions, net$0.00$0.00-$-690K$0.00$0.00
Net cash used for investing activities$740K$910K$7.01M-$-5.13M-$-26.48M
Common stock issued$9.7M$25.5M$11.5M$80K$73.6M
Common stock repurchased$0.00-$-10K-$-40K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.93M$24.5M$2.3M-$-5.8M$78.8M
Net change in cash-$-5.63M$6.85M-$-21.09M-$-54.73M$22.3M
Cash at end of period$8.79M$14.4M$7.58M$22.7M$77.4M
Operating cash flow-$-15.3M-$-18.55M-$-30.44M-$-37.8M-$-30.06M
Capital expenditure-$-20K-$-210K-$-5.74M-$-7.33M-$-5.16M
Free cash flow-$-15.32M-$-18.76M-$-36.17M-$-45.13M-$-35.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About iBio, Inc.

        iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

        CEO
        Martin Brenner
        Employees
        20
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of iBio, Inc. (IBIO)?

        InvestorsCraft does not currently publish an intrinsic value for IBIO. How the IC value is calculated.

        Is IBIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for IBIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.